Abstract
Cochrane Reviews are widely regarded as the gold standard for evidence synthesis, yet analytical framing influences interpretation. A recent Cochrane review of amyloid beta–targeting monoclonal antibodies pools mechanistically and biologically heterogenous interventions. These antibodies differ in biological targets and clinical effects, making a class-level estimate difficult to interpret. Pooling effects across these studies risks obscuring meaningful differences between interventions and may produce conclusions that do not reflect the underlying data, with important consequences for the evaluation of disease-modifying therapies in Alzheimer’s disease.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: | July 28, 2026
Neuro-Dementia